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Abstract 
Over the last decades, the face of health care has changed dramatically, with big improvements in what is technically 
feasible. However, there are indicators that the current approach to evaluating evidence in health care is not holistic 
and hence in the long run, health care will not be sustainable. New conceptual and normative frameworks for the 
evaluation of health care need to be developed and investigated. The current paper presents a novel framework of 
justifiable health care and explores how the use of artificial intelligence and big data can contribute to achieving the 
goals of this framework.
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Background
Every patient expects to receive the best care for their 
problem. Every physician aims to provide the best care 
for their patient. Every public policymaker and politician 
should strive to make the best care available to all mem-
bers of society. All these appear straightforward aspira-
tions, but bringing them into reality rapidly turns out to 
be quite challenging. The face of healthcare has changed 
substantially over the last 2 decades, and continues to 
do so at exponential speed. Fuelled by digitalization and 
artificial intelligence techniques, new interventions and 
diagnostics are being developed, stretching expectations 
on what can be achieved in healthcare to the limits of 
human imagination. The expansion of tools in the field 
of genomics in the last decade has enabled not only the 
analysis but also the modification of the human genome 
[1]. At the same time, healthcare costs are surging rap-
idly, and health is increasingly considered as a consump-
tion good, and thus subject to the workings of the free 
market [2, 3].
In such a setting, what exactly is the best care for a cer-
tain condition? How can we define or know whether A 
is a better intervention than B, who defines this, and on 
the basis of which criteria? Most would argue that this 
can best be found out via randomized controlled tri-
als (RCTs), ideally several of them aggregated in rigor-
ously performed systematic reviews [4, 36]. RCTs have 
the great advantage that, when performed properly, they 
can theoretically directly reveal causal relations between 
an intervention and the effect size of an outcome. There-
fore, most would consider them as the highest rank of 
evidence. However, it might be unclear whether the best 
intervention should be the same for all patients with a 
particular condition? A further question is in which con-
ditions can A be an acceptable treatment, despite being 
less optimal than B? Different answers may arise due to 
various reasons. Patients may have different preferences, 
both with regard to the intervention, as to which out-
come they prefer. For example, some patients on hemo-
dialysis prefer a tunnelled catheter over an arteriovenous 
fistula [5, 6], although the latter are associated with bet-
ter outcomes in observational studies. Furthermore, the 
cost of A can be exuberantly higher than the cost of B, 
while the difference in outcome is minimal. The manage-
ment of hyperkalaemia can be done with (cheap) resins 
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or (expensive) patiromer, but evidence to compare one 
head to head to the other is currently lacking.
What if according to the physician A is better than 
B, but the patient still wants B? What if intervention A 
is best for disease X, but also very expensive and thus 
potentially ruling out the reimbursement of intervention 
B for disease Y (sustainability, fairness, opportunity costs) 
[7]? What if an intervention is good for an individual but 
not for society, for example the unrestricted use of broad 
spectrum antibiotics? What if available information is 
apparently conflicting or contradictory? What if patients 
are lured into treatments that have little or no effect (for 
example by direct to consumer marketing)?
In this paper, we will first elaborate the concept of justi-
fiable healthcare as a means to strive for evidence based, 
efficient, just and sustainable healthcare. We will first 
explore the different steps of justifiable healthcare evalu-
ation, why they are necessary and what the pitfalls and 
bottlenecks are. More importantly, in the second part 
of the paper, we will explore how the use of big data and 
artificial intelligence technology may be helpful in tack-
ling some of the problems in achieving such justifiable 
healthcare, and how it might in contrast generate addi-
tional hurdles and pitfalls [8].
Although a universally accepted definition of big data 
does not exist, most definitions refer to an approach 
which allows for an enormous increase in access to, and 
automated use of, datapoints, and this at a speed beyond 
the ability of classical database software. Frequently men-
tioned additional attributes of big data are the variety of 
the available data and data sources that can be used and 
aggregated. Using algorithms (artificial intelligence), 
these datapoints can be turned into new information 
and knowledge. Routinely collected health data (RCD, 
sometimes also denoted as Real World Data), for exam-
ple obtained from electronic health records or insurance 
claims, but also from wearables or apps, are increasingly 
used for biomedical purposes. This is primarily moti-
vated by the expectation that revealing valuable infor-
mation hidden within these data will improve medical 
decision-making, assist regulatory approval, and reduce 
costs. However, this potential utility inherently hinges 
on data quality which is often compromised by missing, 
miscoded or erroneous entries, maladapted data cap-
ture incentives (upcoding to maximize charges) or server 
shutdowns [9]. For example, it has been debated whether 
the improved outcome of acute kidney injury over the 
last decades is a real improvement or just a bias induced 
by a creeping of the definition in administrative datasets 
[10]. Moreover, setting up collaborative data networks 
poses additional challenges related to interoperability 
and data harmonization [11]. Data coming from differ-
ent sources should first be harmonized and aligned to a 
common data model before they can be used for analy-
sis or knowledge generation. Once this step is taken the 
data should be tested for three main data quality criteria: 
conformance, completeness and plausibility [12]. This is 
rarely a swift process and many real life big data applica-
tions fail in this regard, leading to biased conclusions [13, 
14].
Introducing the concept of justifiable healthcare
The best care is a fragile concept to handle, as it is very 
difficult to define “best”, or even to determine whose 
perspective should be taken when defining “best”: what 
is best from the perspective of A in  situation X may be 
not best from perspective B in situation Y, where A and 
B can be potential stakeholders involved in healthcare 
(patients, family, physicians, policymakers, healthcare 
providers, society, industry..) and X and Y represent dif-
ferent conditions and settings. Therefore, rather than 
considering best care, we introduce the new concept of 
justifiable healthcare.
For the purposes of ascertaining whether a certain 
health intervention is justifiable, we propose a holistic 
approach, informed by different perspectives and disci-
plines, following predefined consecutive steps (Fig.  1). 
Justifiable healthcare differs from good/best care, as it 
implicitly requires the underlying reasoning and argu-
mentation to be made transparent to all stakeholders, 
and the decision to be based on a systematic and holis-
tic approach. This differs from the frequently adopted 
paternalistic approach, where “best” is largely defined 
based on purely biological and technical aspects of care, 
and where the decision is taken in isolation, without con-
sideration of its societal impact, psycho-social aspects or 
what patient needs and values. Indeed, justifiable health-
care implies transparency and evaluation, both at the 
micro-level of the interaction with the patient and at the 
macro-level of society, for example for drug registration 
or reimbursement (Table 1).
As a first necessary but not sufficient step, the evalu-
ation requires consideration of any evidence on the 
efficacy of the intervention. AI and big data can be of 
help to mine and digest existing literature and evidence, 
at a much higher speed and in a more exhaustive man-
ner than is currently possible using human skills. It is 
crucial that for this evaluation of efficacy, standardized 
core outcome sets are applied [15, 16]. These are sets 
including only outcomes that are: relevant to patients; 
measurable in an accurate and reliable manner; and dis-
criminative. At the micro-level of the healthcare pro-
fessional and the patient, justifiable healthcare is in fact 
an essential element to allow for genuine shared deci-
sion making. Indeed, justifiable healthcare provides 
all stakeholders involved with the argumentation and 
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information necessary to decide which intervention has 
the highest probability to lead to the desired outcome 
given this specific condition affecting this specific patient 
and taking into account other available interventions. 
Big data and AI can be of help to present alternative 
options in a way that both patients and healthcare work-
ers can easily understand, and finetuned for the specific 
case of the patient [17]. Big data and AI can also be used 
to emulate clinical trials based on existing routinely col-
lected data [18]. This may enable a more rapid collection 
of evidence on longer term outcomes, including on top-
ics for which randomized controlled trials are deemed 
unfeasible or unethical [19]. The negative effects of 
smoking, or the choice between different renal replace-
ment therapies can be typical examples of such a context. 
Moreover, these methodologies allow for an evaluation 
of dynamic problems, such as the optimal timing of the 
start of certain treatments, or of the succession of differ-
ent regimens, such as cancer treatments [20]. This is not 
feasible with clinical trials due to the myriad of potential 
combinations. Big data approaches can thus have signifi-
cant added value next to randomized controlled trials, 
not only to verify the outcome of randomized trials in 
real world settings, but also to generate knowledge that 
would be difficult to obtain with randomized trials [21].
The second step in our proposed model is an evalua-
tion from the perspective of health economics. At his 
stage, the budgetary impact and opportunity costs of the 
possible interventions that have ‘survived’ the first stage 
(efficacy evaluation) should be taken into consideration.
Inevitably, choices will have to be made during this 
evaluation process, so in addition to applying economic 
criteria, in the third step, the ethical and social aspects 
of the candidate interventions should be explored and 
evaluated to assess whether the intervention is acceptable 
and desirable and to what extent it can be considered to 
be a priority that responds to a true need of (a subgroup 
of ) the population.
The actual performance or outcomes of the intervention 
when applied and implemented in real world conditions 
may of course, for a variety of reasons, differ from what 
was observed under more controlled conditions. There-
fore, it is essential that outcomes of the intervention in 
the clinical reality are monitored, for example by estab-
lishing registries. Such feedback loops not only provide 
opportunities to benchmark providers, thereby adding 
granularity to the information for shared decision mak-
ing at the individual patient level, but also allow for the 
evaluation of effectiveness (i.e. the true effects) of an 
intervention as opposed to its efficacy (Table 2).
Fig. 1 Flow chart of justifiable healthcare
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Uses of big data and artificial intelligence 
for evidence building
Basic science and development
Current biotechnologies such as the different -omics 
analyses generate massive data, the so-called Biomedical 
Big Data (BBD). The results of all these research efforts 
can be dispersed over a wide range of locations, sources 
and specialties. AI based analytical tools are essential 
to sifting through all this information, to detecting pat-
terns, and to giving meaning to the outputs of many tech-
niques currently used in biomedical research, such as 
next generation sequencing, microbiomes, proteomics, 
etc. AI based search engines can retrieve and visualize 
all the available data on certain molecules, thus avoiding 
duplication of research efforts, find new uses for exist-
ing molecules (repurposing) or create new molecules 
with predefined properties [22, 23]. AI can also help to 
generate new molecules for prespecified tasks, based on 
structural or functional similarity with other molecules 
[24]. IBM Watson for Drug Discovery [25] was developed 
for this purpose and was launched with great ambitions, 
although its actual real world performance is considered 
to be a disappointment by many commentators [26]. The 
latest reports on the capacity of DeepMind’s AI to help 
unravel the three dimensional structure of proteins [27] 
demonstrate the potential, but also the narrow applicabil-
ity of such AI systems: they are great at clearly circum-
scribed tasks, but transitioning from in silico or in vitro 
molecular biology to real world clinical applications 
remains very challenging. Understanding the molecular 
basis of disease processes can help identify patients in 
whom certain therapeutic approaches will not work, for 
example because they lack receptors for the intervention, 
or because their pathogenetic process runs through dif-
ferent pathways. Many therefore see AI as the ultimate 
step towards individual patient focused precision medi-
cine. However, unfortunately, biology is mostly more 
complex than this, and in addition, virtually all of these 
deep learning analyses are based on associations and 
not on causal links. A thorough in-depth understanding 
of causal pathway analysis is therefore often essential to 
translate results to clinical practice [8].
Information and evidence gathering
The current rate of publication is such that it substan-
tially outpaces human capacity to read and assimilate 
all information [28]. Therefore, objective and systematic 
methods to search, review, and aggregate published stud-
ies are a fundamental aspect of evidence building [29, 36]. 
Many of the tasks involved are extremely time consuming 
and human resource intensive: setting up and testing a 
search strategy for each of the different databases (Ovid, 
Medline, Pubmed, Central…); exclusion of non-relevant 
papers based on title and abstract; selecting papers based 
on in- and exclusion criteria of the clinical question; data 
extraction and aggregation into the different outcomes 
of interest; applying risk of bias scores to the individual 
papers [30]. All these tasks need to be done in duplicate, 
to avoid errors and bias in interpretation. Moreover, 
information that is not published in indexed journals, 
also called grey literature, is difficult and time-consuming 
to find, yet this literature leads to erroneous conclusions 
[31]. As a result of their laborious character, system-
atic reviews sometimes are already outdated at the time 
of publication. However, as these tasks are repetitive in 
nature, they are in principle ideally suited for automation. 
Most of these tasks are classification problems which 
can be addressed by AI based on natural language pro-
cessing (NPL). Search engines can help plough through 
the worldwide web to find grey literature information in 
abstracts and conference proceedings, and even in the 
Table 2 Pitfalls/problems of big data
Data quality
Completeness of data
 Informative missing data
 Selective




Representative data for the group at hand
Granularity of data















Reporting of non-prespecified analyses
Framing
Unplanned sub-analysis and post-hoc analysis
Inappropriate statistical or methodological approach
Confusing causal and associative interpretations
Confusing statistical vs clinical relevance (the p-value problem)
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data warehouses of administrative organizations such as 
the Federal Drug Administration (FDA) or the European 
Medicines Agency (EMA).
AI systems have been developed for each of these indi-
vidual tasks or combinations thereof. SWIFT-review [32], 
for example, can be used during the scoping phase to 
help formulate questions and identify whether they can 
reasonably be answered based on the available evidence. 
It could also be used to assist in updating existing sys-
tematic reviews. For example, European Renal Best Prac-
tice (ERBP), used the Early Review Organization System 
technology to facilitate and document the first phases 
of screening and selection of papers in the context of an 
international multidisciplinary team [36]. EPPI-reviewer 
[33], used by Cochrane and NICE, not only provides 
tools to retrieve, select and document papers based on 
self-learning algorithms, it can also perform automated 
text coding and data extraction from full papers. As the 
use of such AI based systems could speed up turn-around 
time of systematic reviews, substantially more up-to-date 
systematic reviews could be undertaken. Furthermore, 
more databases, including FDA and EMA and grey lit-
erature, could be explored for information, resulting in 
more in-depth analysis while at the same time reducing 
the impact of publication bias. The latter could easily be 
reduced even more by matching published work with 
pre-registered protocols, again a task for which AI is ide-
ally suited [34]. Furthermore, once set up and trained, the 
AI algorithm could be run on a regular basis and even-
tually update the evidence as new information emerges 
over time (so-called ‘living’ systematic review).
Before these AI based systems could gain widespread 
implementation for systematic evidence review, some 
hurdles remain to be taken however. Crucially, these 
systems will need to provide evidence of non-inferiority 
in comparison with human hand-searched systematic 
reviews [35], so all stakeholders involved can be confident 
that the same high standards apply for both. Although in 
principle evidence review is a time linear process, differ-
ent teams take different approaches to the different sub-
tasks and their timing in the workflow. The different AI 
systems currently available [30] also mostly work as sepa-
rate devices on subtasks of the evidence review process, 
so they need to be integrated in the workflow of the team. 
Using AI can substantially alter the line of thought here. 
For example, all systematic review teams agree that fram-
ing the question (the PICO framework [36]) should be 
the first step before any search or data extraction is done. 
However, using AI, it would be possible to perform the 
data extraction automatically already at the moment of 
publication of a paper, and store the data in a knowledge 
repository for later analysis when the question arises. 
The methodological, epistemological and other potential 
sources of bias of such an approach remain to be investi-
gated. Clearly, in order to be generalizable, an AI system 
should ideally automate all the tasks between the formu-
lation of a question to the presentation of results.
Generation of knowledge from routinely collected data
Current paradigms place randomised controlled tri-
als (RCTs) at the top of the hierarchy of evidence from 
which to derive information. However, RCTs have several 
aspects that make them less suited as sources of evidence 
under certain conditions. First, inherent to the require-
ment for strict in- and exclusion criteria, RCTs typically 
investigate single, well defined and isolated interventions 
in very specific subgroups of the population. Whereas 
this is a strong advantage with regard to the deduction 
of causal relations between intervention and observed 
effect, it also has a downside as it hampers the exter-
nal validity of RCTs [37, 38]. In an era where patients 
increasingly have multiple underlying comorbidities 
rather than one single disease, this is a serious obstacle. 
Moreover, for rare diseases, with treatments tailored 
specifically to particular individuals, simply not enough 
comparable patients might be present to set up a suffi-
ciently powered RCT.
Second, RCTs are very expensive, hence evidence on 
the efficacy and safety of products with limited commer-
cial interest is often lacking. Some commentators suggest 
the use of pragmatic RCTS, whereby in- and exclusion 
criteria are broader and administrative regulation is less 
strict, thus reducing costs. In most settings, such prag-
matic trials de facto are a hybrid between a genuine RCT 
and a prospective, well designed observational trial in 
which part of the population is randomized [39].
Third, RCTs do not solve the problem of what to do 
now, as their results only become available after a signifi-
cant delay. For example, the IDEAL trial on the timing of 
start of dialysis in patients with chronic kidney disease 
took 10 years from the start of the study to the publica-
tion of the results [40]. In addition, it appeared that due 
to the differences in interpretation of the criteria to start, 
the trial actually answered a question different from the 
original question it was randomized for [41]. In the field 
of cardiology, the question on thrombus aspiration dur-
ing percutaneous coronary intervention was solved more 
rapidly based on a large registry trial [39] than with the 
classical RCT [42], even though the budget for the former 
was 30 times lower. In this era with a rapid evolution and 
development of new innovative interventions, the effect 
size of an intervention thus cannot be timely assessed in 
RCTs as, by the time the RCT is finished, new interven-
tions have become available [43]. Due to all these factors, 
knowledge generation in medicine would be incomplete 
and biased if it would only rely on RCTs. The current 
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system is thus suboptimal from an epistemological, ethi-
cal and regulatory perspective, and there is an urgent 
need for complementary ways to generate evidence next 
to RCTs [21].
Besides their use for benchmarking and demonstrat-
ing the value of an intervention in real world conditions 
(see below), routinely collected data can potentially also 
be used to emulate randomized clinical trials, using an 
approach known as counterfactual prediction. In this way, 
routinely collected data can become part of an additional 
or complimentary methodology to RCTs [21]. Admit-
tedly, existing observational datasets frequently do not 
contain the necessary granularity to make an exact emu-
lation possible, but about three quarters of trials contain 
sufficient data to reasonably do so [14]. First, using this 
technique, data from an existing randomized controlled 
trial can potentially be generalized to a broader popula-
tion. In this way, the validity of the effect size beyond that 
of the original trial population defined by specific in- and 
exclusion criteria can be established (Fig.  2). It can also 
be used to explore transportability [44], i.e. to explore 
the validity of effect sizes in a population that substan-
tially differs from the trial population [45]. Both condi-
tions are becoming increasingly common, as the number 
of patients with more than one comorbidity is rapidly 
increasing.
Second, the approach of counterfactual prediction 
potentially enables the simulation of an as yet non-exist-
ing randomized clinical trial based on routinely collected 
data [19]. If such simulation would be successful, the 
need for expensive RCTs could potentially be avoided, 
and desired evidence might be obtained more rapidly [39, 
42]. Furthermore, RCTs can be considered unethical or 
simply not feasible in certain settings.
Third, the number of potential interventions for any 
particular condition is growing rapidly, and often these 
different interventions can be administered in a certain 
order. For example in HIV or cancer treatment, the suc-
cession of different drugs or even types of interventions 
(radiotherapy, chemotherapy, surgery) will need to be 
evaluated as these diseases tend to become chronic con-
ditions, requiring different treatments at different points 
in time (first line vs second line, attack vs maintenance 
etc.). Also in renal replacement therapy, it is unclear 
which succession of available treatments (hemodialy-
sis, peritoneal dialysis, transplantation) yields the most 
optimal outcomes over the life span of the patient [46]. 
It is nearly impossible to explore all potential combina-
tions and successions of these treatments through RCTs. 
The optimal timing of an intervention, such as starting 
renal replacement therapy for acute kidney injury, can 
also be difficult to explore in RCTs. Due to the necessar-
ily strict definitions used in RCTs for deciding the timing 
of “early” versus “late” start of renal replacement, in the 
different available RCTs de facto different strategies are 
compared, explaining differences in outcome. However, 
it is clear that not all potential definitions of “early” and 
“late” start can be explored in RCTs.
Such dynamic problems could potentially be explored 
based on routinely collected data, provided that appropri-
ate analytical techniques are used [20]. Emulating RCTs 
based on routinely collected data could potentially gener-
ate evidence in these circumstances, with the advantage 
that evidence can be updated as new cases come in. Link-
age of routinely collected data with RCT data may also 
leverage RCT findings by enabling increased statistical 
power, allowing RCTs to be stopped earlier [47], allowing 
for the identification of relevant effect modifiers, so that 
treatments can be tailored based on certain markers [48], 
and earlier validation of surrogate endpoints [49].
Shared decision making: explaining evidence to patients
Shared decision-making (SDM) is increasingly advo-
cated as the preferred conceptual framework for deci-
sions at the individual patient level [50]. The three pillars 
involved in this decision process are the evidence base, 
the clinical expertise of the healthcare worker and the 
preferences and values of the patient. The healthcare 
worker tries to inform the patient on probabilities that 
intervention A will result in desired outcome X and not 
an undesired outcome Y, as verbalized by the patient, 
taking into account the situation of the patient. However, 
it is essential that the patient and physician can obtain, 
understand and correctly interpret the information pro-
vided. As both patients [51] and physicians [52] often 
lack basic statistical literacy, information needs to be pre-
sented in a way that helps them gain insight in the data 
and their meaning in a simple, informative and straight-
forward way [53, 54].
Fig. 2 Concepts of generalizability and transportability of data from 
randomized controlled trials
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It is therefore crucial to develop easily understand-
able presentation paradigms that allow for the integra-
tion of all available evidence with the specific condition 
of the individual patient, helping her to make a decision 
that leads to a result as close as possible to her prefer-
ences and values. A healthcare worker has an obligation 
to first elicit the true values and life goals of the patient 
before considering a treatment. No interventions should 
be made to achieve outcomes that are of no value to a 
given patient, for example interventions that are only 
intended to optimize surrogate outcomes which are irrel-
evant to the patient. The proposed treatment should be 
that which has the highest probability of achieving these 
values and life goals. Situations may of course arise in 
which the values of the healthcare worker and those of 
the patient differ and where, from the perspective of the 
healthcare worker, a suboptimal decision is made. The 
shared decision making process is akin to a balanced 
negotiation process wherein both parties try to achieve 
the best decision. The stronger the evidence (for example 
several large randomized controlled trials with similar 
results), and the more important the outcome (for exam-
ple an important improvement in survival), the greater 
the effort the healthcare worker must make to convince 
the patient. Graphical representations of the projected 
outcome of different treatment alternatives can be con-
structed in real time by algorithms based on routinely 
collected data, containing features similar to the target 
patient, but treated with the different alternative treat-
ments available [17]. Such real time visualizations of the 
different options can be used to help achieve the goal of 
genuinely shared decision making [17, 53].
The need for core outcome sets
If we intend to use aggregated evidence from randomized 
trials and observational studies to assess outcomes that 
are relevant for patients, it is essential to create stand-
ardized core outcome sets [15]. A core outcome set is a 
compilation of well-defined outcome domains relevant 
to patients, with a unified, well circumscribed definition 
of the measure used to evaluate the outcome domain, 
and the desired way to report it. The unique definition 
is essential to allow for aggregation of data across stud-
ies and to ensure that each study reports on the same 
construct of the outcome. Currently, many outcomes are 
ill-defined and have different meaning in different stud-
ies, leading to misinterpretation and confusion [55]. Even 
when there is a unified definition, the interpretation and 
application of this definition should be as uniform as 
possible. Differences in what is reported as an outcome 
substantially limit the progress of knowledge and make 
the aggregation of evidence difficult if not impossible, as 
such differences result in comparing apples and oranges. 
Moreover, using standardized outcomes will decrease 
research waste, as studies will only investigate those out-
comes that are relevant to patients and society. There is 
a growing understanding of the importance of this prob-
lem by scientific organisations [56–58]. Some administra-
tive and commercial initiatives have also been launched 
in this regard, e.g. ICHOM (International Collaborative 
on Health care Outcome Measures) [59].
Acute kidney injury is a clear example. For a long time, 
a unified definition was lacking, leading to a wide diver-
gence in reported incidence, prevalence and outcomes 
[10]. Over the last years, a unified definition has been for-
mulated and accepted [60], yet the practical interpreta-
tion and implementation of this “unified” definition still 
is open to interpretation [61], with substantial impact on 
reported incidence, prevalence and outcome of AKI [62]. 
When data are aggregated in big data sets, it is essential 
that the constructs that are represented by those data 
are defined and measured as uniformly as possible. If 
not, the “tank problem” [63] might arise, i.e. patients are 
categorized based on criteria that are not linked to their 
underlying pathology, but to some other, mostly technical 
aspect. This has been found, for example, with regard to 
the automated diagnosis of pneumonia, where diagnosis 
was strongly influenced by the type of X-ray device used 
for imaging [64].
To be useful in Shared Decision Making, standard-
ized outcomes should also be relevant for all stakehold-
ers [16]. This means that patients should be involved 
in constructing and selecting the outcome variables of 
interest, how they should be measured and which differ-
ence in that outcome is relevant to them [65]. The need 
for standardized outcomes will be further exacerbated if 
we start using AI to explore evidence. AI will either used 
predefined terminology, so it can search for predefined 
terms, or natural language processing to extract concepts 
from existing texts. In both cases, standardization of the 
outcomes is essential. If AI uses predefined concepts in 
its search, we need to ensure that these concepts all have 
the same meaning in the primary sources, for otherwise 
information will be lost and may even be wrong, as an 
apple might not always truly be an apple. If we are going 
to use natural language processing, there are strong rea-
sons to be concerned that AI will get stuck in the under-
standing the true meaning of expressions it encounters 
during the text analysis and in placing them in a general 
context, a task that can easily be performed by humans, 
but is very hard for AI.
The use of big data in health economics analysis 
(affordability and prioritization)
Over the last decades, healthcare expenses have surged 
exponentially. Although partially explained by the ageing 
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of the population, the bulk of this increase can be attrib-
uted to a steep increase of technological interventions, 
both in terms of availability and accessibility, as well as to 
the cost of these interventions. It is obvious that there is a 
limit to the total budget that can be spent on healthcare, 
which inherently implies that choices need to be made 
all the time. To ensure that these choices result in justifi-
able healthcare, a thorough analysis is necessary. First, an 
assessment of the cost of the intervention in relation to 
its potential impact needs to be performed. The indica-
tor of “quality adjusted life years gained” (QALY) is most 
frequently used in this context. The utility of an interven-
tion is based on available evidence regarding the esti-
mated effect size, with systematic reviews being the ideal 
instrument to calculate these. As mentioned earlier, big 
data and AI can be used to help perform such systematic 
reviews if they are lacking.
Second, the budgetary impact of the intervention needs 
to be assessed, i.e. the cost of the intervention times the 
number of persons in the society who would potentially 
benefit from that intervention. Registry data can be used 
to assess these. In nephrology, for example, registries 
could establish the number of people with diabetes mel-
litus type 2 and micro- or macro-albuminuria, thus also 
assessing the number of people who could potentially 
benefit from a drug that retards progression of kidney 
disease. Ideally, data on the degrees of comorbidities in 
this population should also be available, to assess the 
extent to which available evidence can be generalized to 
this specific real-world population, in order to estimate 
the true effect and thus the real expected QALYs, as 
described above.
Evidence from trials and registries could potentially 
be complemented by real world data from wearables, 
handheld devices and social media to help assess the 
utility of interventions in everyday living conditions of 
patients [66]. Many more databases pertaining to people 
with different backgrounds are needed for health eco-
nomic analysis than in the case of effect size estimation. 
For example, in order to estimate costs, not only data on 
the incidence and prevalence of disease conditions and 
data regarding costs are needed, but also information 
on the extent of the associated comorbidities and their 
distributions.
Given that all of these data need to be integrated, the 
use of big data for the purposes of health economics anal-
ysis might be jeopardized even more by concerns on data 
management and data quality in the data sources and the 
analytical techniques used [67]. Data management issues, 
such as data storage, computation power, opaque access, 
integration and linkage of datasets, and ensuring the 
uniqueness of used definitions, can be mitigated by cre-
ating standardized approaches to storage and definitions 
of data. Still then, the cost of creating and/or accessing 
all these datasets might be prohibitive for health econo-
mists to access and integrate all the databases they ideally 
would need to feed their models. Most machine learning 
algorithms are developed for prediction based on associ-
ations, for which they perform quite well. However, pre-
diction is quite different from estimating the effect sizes 
of interventions, where it is essential that the relation 
between variables and outcome is causal. When apply-
ing machine learning in comparative health economics, it 
is moreover essential that the algorithms can handle the 
data in a counterfactual way: what would have happened 
if, instead of intervention A, intervention B would have 
been implemented? [68].
It is an open question whether official bodies should 
accept observational data, even when “big”, as a substi-
tute for randomized controlled trials [69]. Nevertheless, 
the US and European drug regulators (cf. the Twenty-first 
Century Cures Act in the US and the Adaptive Licensing 
approach in the EU) propose that in some cases Phase 
III trials could be replaced by post-marketing evidence 
based on routinely collected data studies [70]. This par-
adigm shift not only entails ethical and regulatory chal-
lenges, but also substantial methodological challenges 
because drawing valid causal conclusions from routinely 
collected data necessarily relies upon crucial assumptions 
about the causal structure of the real world beyond what 
is encoded in the data. This fundamentally changes the 
paradigm of the safety and effectiveness assessment from 
a process with clearly distinctive phases to a continuous 
process in which post-marketing evidence derived from 
routinely collected data plays an important role [71].
Likewise, for medical devices, the new Medical 
Device Regulation (MDR) (Regulation (EU) 2017/745) 
in the EU indicates an evolution towards the increased 
importance of post-marketing surveillance based on 
routinely collected data. Increased use of routinely col-
lected data could provide valuable information on safety 
and effectiveness but the credibility, transparency and 
enforceability of their role in post-market surveillance 
should be explored and demonstrated [72–75]. Various 
remaining regulatory uncertainties, for example regard-
ing the need to make public whether or not post-approval 
studies have begun, or the timing of confirmatory clinical 
trials, have spurred criticisms that such procedures might 
progressively lead to de-regulation [70, 72, 74].
The use of big data for safety and benchmarking
Safety monitoring and  surveillance outcomes of  inter-
ventions According to some commentators, systems 
based on available routinely collected data can potentially 
accommodate for some of the limitations of monitoring 
based on spontaneous reporting, considered as a cor-
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nerstone so far [76], such as the underreporting of non-
obvious side effects. Several pilot programs in the US (e.g. 
OMOP and the Sentinel initiatives), the EU (e.g. EU-ADR 
and PROTECT) and Asia (e.g. Asian Pharmacoepidemi-
ology Network or AsPEN) assess the potential of rou-
tinely collected data for pharmacovigilance and routine 
signal detection. However, partly due to limited statistical 
standards for risk assessment, none of these initiatives has 
convincingly provided credible or reproducible evidence 
of unexpected adverse drug reaction or confirmation of 
known harms [73]. A literature review has compared a 
broad range of analytical approaches and identified tra-
ditional pharmaco-epidemiological designs (in particular, 
self-controlled designs) and sequence symmetry analy-
sis as two of the most promising approaches for signal 
detection in routinely collected data [76]. An outcome-
wide approach [77] to pharmaco-epidemiological designs 
based on propensity score analysis may considerably 
reduce modelling and computational demands, thereby 
increasing their suitability for routine signal detection, 
with a minimal risk of bias.
Benchmarking and  effectiveness Although RCTs con-
tinue to rank high in the pyramid of evidence, they suffer 
from some inherent problems such as a lack of generaliz-
ability and transportability, as discussed above. In addi-
tion, for some interventions, the way in which RCTs are 
implemented in real clinical practice could substantially 
impact the difference between the effect size in real life 
and that the effect size observed in RCTs, where condi-
tions are mostly optimal. For technical interventions such 
as surgical operations, catheterisations, and diagnostic 
procedures, the skill and expertise of the operator can 
have a substantial impact on the final outcome and will 
determine whether the results can be replicated or not. If 
the operator has much skill and experience with interven-
tion B, in her hands the outcome with this intervention 
B could result in better outcomes than with intervention 
A, even if in a randomized trial where A was applied by 
operators skilled in A, the latter was superior.
Currently, the quality of delivered healthcare is mostly 
the result of team work and of a succession of events, 
from correct referral over correct diagnostic procedure 
and interpretation, to correct identification and attention 
to safety and a culture to avoid accidents, including basic 
nursing care. Hence it is not only the individual skill of 
an individual operator or one single intervention that will 
determine the final result, but rather the full chain of all 
processes and people involved in the total process. Even 
for simple interventions, such as the dosing of dialysis 
for acute kidney injury, differences in outcomes between 
RCTs can be explained by differences in overall practice 
between centres [78]. Typically, with studies done in the 
setting of a single centre, exceptional attention is given to 
all study participants, as the team believes in the investi-
gated treatment, which is far less so in multicentric trials. 
The routine collection of outcome data offers opportuni-
ties to evaluate and illustrate the performance of health-
care providers at both the micro level of the individual 
provider and the meso level of the organization. The 
technical possibilities of Big Data approaches allow for 
collection of the data necessary to produce such evalua-
tions from different sources and turning them to a mean-
ingful construct. For example, the outcome of a cancer 
intervention can be assessed by accessing laboratory, 
pathology or radiology data warehouses to collect data 
from an individual diagnosed with the cancer, and link-
ing them with the persons involved in the care as well as 
to other outcomes such as mortality, medical costs, social 
welfare and employment, need for societal support and 
other parameters derived from various other available 
datasets.
From all these data, algorithms can derive different 
markers of performance. The latter can subsequently be 
used as feedback to the healthcare workers (formative 
evaluation), or to inform patients on the performance 
of different healthcare institutions/providers in domains 
that might be of interest and value to them. In this way, 
Big Data could contribute to value based healthcare [79] 
and shared decision making. Whereas the strict techno-
logical requirements to assemble such online reposito-
ries will probably be resolved in the near future, some 
more fundamental methodological questions remain 
to be answered before such systems can be safely and 
effectively used in clinical practice. The selection of the 
most relevant constructs to reflect “performance” has 
been discussed already (cf. supra) and should follow the 
same procedures as those for establishing standardized 
core outcome sets. Furthermore, it should be questioned 
how the feedback to healthcare professionals should be 
structured and organized in order to to achieve a true 
improvement in the quality of care provided. Currently, 
most of these systems use a benchmarking against a 
mean. However, there is evidence that follow up of per-
formance of an individual over time or comparison with 
accepted and established criteria might be much more 
effective to induce a positive change in behaviour [80]. 
Finally, one should be careful when designing the presen-
tation of data to patients, as they can struggle with inter-
preting the information offered [17].
Patient reported outcomes/patient reported expe-
riences Patient perspectives and experiences are 
increasingly gaining interest. Patient-reported outcome 
measures (PROMs) and experience measures (PREMs) 
are mostly questionnaires that assess patients’ health, 
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health-related quality of life and other health-related 
constructs. They can be used to evaluate performance 
or as a benchmark to inform patient choice for health-
care. However, when used intelligently, the information 
can also be used to discover unmet needs or preferences 
in the approach and management of certain health 
conditions or patient groups, assess the effectiveness 
of different treatment plans, monitor disease progres-
sion, stimulate better communication, promote shared 
decision making and issue tailored advice and education 
[81–83]. PROMS and PREMS allow for the visualiza-
tion of the outcome of certain interventions in some of 
the real treatment centres available in the region of the 
patient rather than results obtained in the highly con-
trolled setting of an RCT.
Patient reported outcomes and experiences mostly 
are collected as a one-off (cross-sectional) assessment, 
most frequently using pencil and paper, resulting in a 
burden for patient and staff. As a consequence, sur-
veys are restricted in size, decreasing the relevance and 
spectrum of the topics explored. The advent of new 
digital technologies opens the door to more continu-
ous, in-depth and online reporting of symptoms and 
experiences of patients, in a more feasible, sustainable 
and cost-effective way [84]. In the most simple format, 
patients can use a tablet or handheld device to com-
plete questionnaires during waiting times in the hospi-
tal. More sophisticated systems allow for a continuous 
reporting of symptoms and outcomes through smart-
phones or wearables. Some systems rely on algorithms 
that infer treatment recommendations or advice to plan 
earlier consultations from the data provided [85]. Such 
systems for digital symptom reporting can have a posi-
tive impact on the quality of healthcare with reduced 
symptom distress, improved symptom burden through 
better self-management, improved health-related qual-
ity of life and higher quality of interaction with health-
care professionals.
Going one step further would be to track patient 
data continuously, for example by using smartwatches 
to register heartbeat, or geolocation to assess mobil-
ity, activity and independence as a surrogate of well-
being [66]. Even ‘smart’ pills, monitoring adherence 
to medication intake, are possible these days using AI 
technology [86]. Although attractive at first sight, many 
unresolved issues remain before such systems can be 
more widely used [86]. Major points of concern are the 
safeguarding of privacy and the likely impact on atti-
tudes of insurance companies and healthcare organi-
zations when the possibility of eavesdropping on all 
movements of patients all of the time makes it easier to 
distinguish high and low risk patients from their point 
of view.
Conclusions
Over the last decades, the face of health care has 
changed dramatically. New technologies and inter-
ventions are being developed at exponential speed. At 
the same time, the type of health problems has shifted 
from patients with a clearly defined single and mostly 
acute condition to patients with progressively more 
comorbidity and chronic diseases. Assessment of the 
effectiveness and efficacy of interventions in such a set-
ting becomes more difficult, and requires the evidence 
derived from randomised controlled trials to be com-
plemented with evidence derived from routinely col-
lected data. However, we need to ensure that the right 
methodological approaches are used and that data 
curation is done with utmost attention to quality.
New interventions also put additional pressure on 
an already spiralling health care budget. Therefore, not 
only the effectiveness of an intervention, but also the 
social impact and the overall budgetary consequences 
should be taken into account. To enhance patient cen-
tredness of health care, tools are needed to support 
shared decision making. Ideally, this should be done 
using data from the centre where the patient will be 
treated, and it should be based on outcomes in patients 
as similar as possible to the target patient. Here, too, 
big data and AI could potentially be helpful to explain 
and visualize the effect of different interventions to 
patients. In this paper, we have proposed a novel frame-
work to help evaluate whether interventions will result 
in justifiable healthcare, i.e. healthcare that is effica-
cious, fair, equitable and sustainable. We have identi-
fied where big data and AI could potentially be helpful 
in this evaluation. Further research is needed to explore 
the epistemological, legal and ethical challenges of the 
use of big data and AI within this framework.
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